At a glance
ClinicalIndex Comparison RecordN/ACompleted· 297 enrolled
Drug / intervention
SpyGlassdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Registry to Assess Performance and Clinical Utility of the SpyGlass Direct Visualization System
In Brief
An observational study evaluating SpyGlass for Biliary Tract Diseases. Completed, enrolled 297 participants across 15 sites in 6 countries.
Detailed Summary
A prospective, multi-center registry for subjects undergoing Endoscopic retrograde Cholangiopancreatography (ERCP) and cholangioscopy for known or suspected pancreaticobiliary disease.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Diseases
CountriesBelgium, Denmark, France, Germany, Italy, United States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
Primary CompletionApr 2008
First PostedSep 2008
Study CompletionOct 2009
TodayJul 2026
First PostedSep 12, 2008
Enrollment StartNov 1, 2006
Primary CompletionApr 1, 2008
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.8 years ago
Interventions
SpyGlassdevice
The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.